Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs MTBVAC (Primary) ; BCG
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Biofabri
- 12 Feb 2019 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 12 Feb 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Feb 2020.
- 12 Feb 2019 Status changed from not yet recruiting to recruiting.